[In Focus] A communitarian approach to cell therapy and gene therapy access in low-income and middle-income countries

In low-income and middle-income countries (LMICs), access to both existing and emerging therapies can be limited. Novel cell and gene therapies (CGT)—such as chimeric antigen receptor T-cell therapies for blood cancers and gene therapies for sickle cell disease—are particularly resource intensive. Expanding global access risks exacerbating resource constraints in LMICs due to high costs, complex manufacturing, and the need for extensive care-delivery infrastructure.